10-Q: Bakhu Holdings Reports Q2 2024 Results, Secures $1.03 Million in Financing and Appoints New Directors

Bakhu Holdings reports a net loss of $1.25 million for the six months ended January 31, 2024, while securing $1.03 million in financing and expanding its board of directors.

Summary

• Bakhu Holdings, Corp. filed its Form 10-Q for the quarter ended January 31, 2024, reporting a net loss of $120,680 for the three months and $1,252,158 for the six months ended January 31, 2024.
• The company generated no revenue during these periods, consistent with the prior year.
• Operating expenses decreased significantly compared to the same periods in 2023, primarily due to a reduction in stock-based compensation.
• The company recorded a gain of $323,078 on the settlement of debt with VO Leasing Corp.
• Bakhu Holdings secured $1.03 million in financing through the sale of convertible secured promissory notes.
• The company expanded its board of directors by appointing three new members: Teddy Scott, Mitch Kahn, and Kimberly Tanami.
• The company estimates it will require a minimum of $8.5 million in external capital to continue operations over the next 12 months.
• The company is seeking an additional $9.0 to $19.0 million through the sale of convertible secured notes to reduce liabilities and fund operations.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including ongoing losses, lack of revenue, and a going concern warning. While the company has secured some financing and added experienced directors, the overall outlook is negative due to the company's financial instability and dependence on further capital raises.

Positives

• The company successfully negotiated a debt settlement, resulting in a gain of $323,078.
• Bakhu Holdings secured $1.03 million in financing through the sale of convertible notes.
• The company expanded its board of directors with the appointment of three experienced industry professionals.
• Operating expenses decreased significantly compared to the same periods in 2023, primarily due to a reduction in stock-based compensation.

Negatives

• The company continues to operate without generating any revenue.
• Bakhu Holdings reported a net loss of $1.25 million for the six months ended January 31, 2024.
• The company has an accumulated deficit of $48,731,646 as of January 31, 2024.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal controls.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company has not generated any revenue to date and is subject to risks inherent in establishing a new business.
• The company has an accumulated deficit of $48,731,646 as of January 31, 2024.
• The company has identified material weaknesses in its internal controls.
• The company is seeking additional capital through the sale of convertible notes, which could dilute existing shareholders.
• The company's ability to attract debt financing is impaired by its lack of revenue and a robust trading market for its stock.
• The ongoing conflict in Ukraine and the Middle East may negatively impact the company's commercialization efforts.

Future Outlook

The company plans to commercialize its licensed technology through joint ventures, strategic partners, sublicenses, and other arrangements. They will need additional financing to begin these commercialization efforts. The company is seeking $9.0 to $19.0 million in additional funding through convertible secured notes to reduce liabilities and fund operations.

Management Comments

• Management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable.
• Management states that the company will need additional financing from external sources to begin commercialization efforts.
• Management estimates that the company will require a minimum of approximately $8.5 million in external capital to continue and to fund activities during the next 12 months.
• Management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our results of operations, financial position or liquidity for the periods presented in this report.

Industry Context

The company operates in the cannabis industry, which is subject to evolving regulations and market conditions. The company's focus on cell-extraction and replication technology positions it within the biotechnology sector of the cannabis market. The company is seeking to partner with experienced cannabinoid production firms to commercialize its technology.

Comparison to Industry Standards

• The company's lack of revenue is not uncommon for early-stage biotechnology companies focused on research and development.
• The company's reliance on related-party loans is a common practice for companies with limited access to traditional financing.
• The company's focus on licensing its technology is similar to other biotechnology companies that seek to leverage their intellectual property.
• The company's need for additional capital is typical for companies in the cannabis industry, which often require significant investment to scale operations.
• The company's debt settlement and restructuring efforts are similar to other companies facing financial challenges.

Management Changes

Corporate Governance

Related Party Transactions

• The company has significant related party transactions, including notes payable to Cell Science Holding Ltd. and The OZ Corporation.
• The company has an Office Cost Sharing Agreement with The OZ Corporation, with $1,205,000 due for unpaid space sharing fees as of January 31, 2024.
• The company has a $3.5 million promissory note to Cell Science, bearing interest at 0.44%, due December 31, 2027.
• The company has a convertible note payable to The OZ Corporation dated August 1, 2019, with interest at 6%, due December 31, 2027.
• The company has a note payable to The OZ Corporation dated June 23, 2022, with interest at 7%, due December 15, 2024.
• The company has a Convertible Senior Secured Promissory Note payable to OZ Company, with interest at 13%, due February 27, 2028.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of convertible notes and stock options.
• Employees may be impacted by potential cost-cutting measures if the company does not secure sufficient funding.
• Creditors may be impacted by the company's efforts to reduce liabilities through debt restructuring.
• Customers and suppliers may be impacted by the company's ability to commercialize its technology and generate revenue.

Next Steps

• The company will continue to seek additional financing through the sale of convertible secured notes.
• The company will allocate a portion of incoming funds to repay current liabilities and operating expenses.
• The company will advance its proposed technology customization and refinement and licensing efforts.
• The company will seek to appoint a seventh independent director to the board.
• The company will continue to implement its commercialization plan.

Key Dates

Keywords

cannabis, biotechnology, financing, convertible notes, board of directors, financial results, net loss, operating expenses, stock-based compensation, debt settlement, going concern, internal controls